Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule

P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

1996 • 1,268 citations

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.

1992 • 532 citations

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

1997 • 474 citations

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

1991 • 444 citations

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.

1995 • 302 citations

Prediction of Carboplatin Clearance From Standard Morphological and Biological Patient Characteristics

1995 • 243 citations

Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.

1990 • 217 citations

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

1998 • 176 citations

Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy

1987 • 155 citations

Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro

1994 • 129 citations

Morphologic variations of small cell lung cancer: A histopathologic study of pretreatment and posttreatment specimens in 104 patients

1986 • 89 citations

Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.

1997 • 89 citations

Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study.

1990 • 83 citations

Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.

1987 • 79 citations

Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung

1986 • 72 citations

VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer

1984 • 68 citations

Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients.

1992 • 67 citations

Immunohistochemical detection of DNA topoisomerase IIα, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer

1998 • 59 citations

Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer

1993 • 58 citations

Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients.

1991 • 50 citations

The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16–213, doxorubicin and vincristine (VPAV) for small cell lung cancer

1988 • 44 citations

Histologic changes in small cell lung carcinoma after treatment

1996 • 34 citations

Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer

1996 • 34 citations

Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: A phase II study of the EORTC lung cancer cooperative group

1993 • 29 citations

Second line chemotherapy in small cell lung cancer

1989 • 28 citations

Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma

1996 • 27 citations

Second-line chemotherapy in small cell lung cancer

1990 • 21 citations

Immunohistochemical detection of P-glycoprotein and carcinoembryonic antigen in small cell lung cancer: with reference to predictability of response to chemotherapy.

1993 • 19 citations

Identification of new drugs in pretreated patients with small cell lung cancer

1989 • 18 citations

A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer

1989 • 15 citations

Treatment of relapsed small cell lung cancer

1994 • 6 citations